Muscle health can be rapidly compromised in clinical environments. Modifiable strategies to preserve metabolic homeostasis in adult patient populations include physical activity and pharmacologic support; however, optimizing dietary practices, or more specifically protein intake, is a necessary prerequisite for any other treatment strategy to be fully effective. Simply increasing protein intake is a wellintentioned but often unfocused strategy to protect muscle health in an intensive care setting. Protein quality is a frequently overlooked factor with the potential to differentially influence health outcomes. Quality can be assessed by a variety of techniques, with digestible indispensable amino acid score being the current and most comprehensive technique endorsed by the Food and Agriculture Organization. In practical terms, animal-based proteins are consistently scored higher in quality compared with incomplete proteins, regardless of the assessment method. Consequently, choosing parenteral and/or enteral feeding options that contain high-quality proteins, rich in the branched-chain amino acid leucine, may help establish a dietary framework with the potential to support clinical practice and improve health outcomes in critically ill patients. Caspase-3 is a protease that facilitates the destruction of intact muscle fibers to release monomeric contractile proteins such as actin and myosin for degradation by the ubiquitin-proteasome system into amino acids.
The accelerated loss of skeletal muscle and functional capacity that accompanies even brief periods of hospitalization, injury, or illness is debilitating and has considerable impact on healthcare systems. 1, 2 Identifying and refining therapeutic interventions to protect and preserve skeletal muscle and metabolic health in adults during periods of catabolic crisis are a priority for clinicians and biomedical researchers. Advancing our understanding of clinical nutrition has the potential to enhance all other treatment modalities. To this end, encouraging a multidisciplinary research approach, integrating clinical trials with basic science, provides a path to enhance our understanding of the potential of dietary protein to positively influence skeletal muscle metabolism in the intensive care unit (ICU).
Role of Branched-Chain Amino Acids in Muscle Accretion
During periods of stress, the human body requires a greater quantity of all essential amino acids to effectively build and repair skeletal muscle and other tissues. [3] [4] [5] In clinical populations, the balance between muscle protein synthesis and breakdown is disrupted. Catabolism is often increased, while postabsorptive and postprandial muscle protein synthesis may be depressed (eg, inactivity) or elevated (eg, hypermetabolism). 4, [6] [7] [8] [9] [10] To provide a mechanistic basis for ongoing clinical efforts and research interventions, a large number of studies continue to focus on the regulation of intracellular signals that control muscle growth and breakdown. 7, 8, [11] [12] [13] To stimulate protein synthesis, amino acids and branchedchain amino acids, in particular, must enter the muscle cell via active transport. Both physical activity and protein ingestion stimulate the messenger RNA (mRNA) expression of a number of amino acid transporters (ie, large neutral amino acid transporter small subunit 1/solute carrier family member 5 [LAT1/SLC7A5], sodium-coupled neutral amino acid transporter 2/solute carrier family 38 member 2 [SNAT2/SLC38A2], cationic amino acid transporter1/solute carrier family 7 member 1 [CAT1/SLC7A1]). However, some age-related differences could provide targets for future clinical trials. 8, 13 For example, in a bedrest research study enrolling healthy older adults, 7 days of inactivity blunted the normal amino acid-induced increase in SNAT2 and LAT1 protein expression. 8 This is broadly consistent with the concept of anabolic resistance (ie, decreased anabolic response to a previously effective stimulus: insulin, amino acids, or physical activity). [14] [15] [16] [17] [18] Protein synthesis occurs through activation of a signaling pathway that stimulates translation of mRNA into protein.
Translation involves activation of the mechanistic target of rapamycin (mTOR). The complex consists of mTORC1 and mTORC2 proteins that, when stimulated, activate several kinases, including S6 kinase (S6K) and eukaryotic translation initiation factor 4E (eIF4E). 19, 20 This, in turn, stimulates mRNA binding to the 43S ribosomal complex and dephosphorylation of the eukaryotic elongation factor 2 (eEF2) for elongation of the peptide chain (Figure 1 ). 21, 22 Protein synthesis rates commonly decline with age due to decreased translation activation and a reduction of the signaling proteins. [23] [24] [25] [26] [27] Sepsis and systemic inflammation also decrease the effectiveness of translation of mRNA into protein in muscle and increase protein synthesis at the liver by activation of the translational machinery. 21, 28 Protein degradation in skeletal Caspase-3 is a protease that facilitates the destruction of intact muscle fibers to release monomeric contractile proteins such as actin and myosin for degradation by the ubiquitin-proteasome system into amino acids. 30 Caspase-3 activity is inhibited by protein kinase B, an insulin-signaling protein. In models of sepsis, the mechanisms causing muscle atrophy include activation of the ubiquitin-proteasome system, leading to accelerated degradation of muscle protein. 31, 32 Recent studies in a model of neonatal sepsis reported that energy and substrate sensing is affected by chronic infection, and this response can be modulated by insulin, 33 and that supplementation of amino acids antagonizes autophagy signal activation in skeletal muscle of neonates during endotoxemia. 34 Of the 9 essential amino acids, the branched-chain amino acids (BCAAs; leucine, isoleucine, valine) serve as building blocks for new proteins and also as regulatory signaling molecules. Leucine, in particular, is an insulin secretagogue and potent activator of the , eukaryotic translation initiation factor 4E-binding protein 1; AKT, protein kinase B; AMPK, 5' adenosine monophosphate-activated protein kinase; eIF2α, eukaryotic translation initiation factor 2α; eIF2B, eukaryotic translation initiation factor 2B; eIF4E, eukaryotic translation initiation factor 4E; eIF4G, eukaryotic translation initiation factor 4G; FoxO1, forkhead box O1; FoxO3, forkhead box O3; FoxO4, forkhead box O4; IRS1, insulin receptor substrate 1; Met-tRNA, Met-charged initiator -transfer RNA; mTOR, mechanistic target of rapamycin; P, phosphorylated; PI 3-K, phosphatidylinositol 3-kinase; rpS6, ribosomal protein S6; S6K1, ribosomal protein S6 kinase beta-1; TSC1, tuberous sclerosis complex1; TSC2, tuberous sclerosis complex 2. mTOR nutrient and energy-sensing signaling pathway. 35 Leucine also has the mechanistic potential to reduce muscle protein breakdown, but the technique to assess breakdown (eg, fractional breakdown rate [FBR] ) is relatively complex and challenging to perform in applied meal-like settings. 36, 37 Several acute human studies suggest that supplementing meals with a relatively small amount of leucine (approx. 3-4 g/ meal) may act as a "trigger" and improve or normalize muscle protein synthesis in aging muscle. 38, 39 For example, in healthy, community-dwelling older adults, the addition of 4 g leucine to a mixed-nutrient meal substantially increased muscle protein synthesis (0.05 ± 0.01%/h vs 0.08 ± 0.01%/h, P < .05). 40 Similarly, in a cohort of middle-aged adults, 3-4 g leucine added to each meal partially protected lean leg mass but only during the first week of a 14-day bedrest study. The time-sensitive protective effect was facilitated by the partial preservation of muscle protein synthesis and accompanied by the partial conservation of muscular strength, endurance, and aerobic capacity. 41 While data from bedrest and acute research studies are encouraging, leucine supplementation is not unconditionally effective, and there is a lack of information on its use in clinical populations or via enteral or parenteral administration routes. Specifically, supplemental leucine may be of limited benefit for active individuals habitually consuming a protein/leucine-sufficient diet (ie, >1.0 g/kg body weight/d). For example, researchers reported no change in skeletal muscle mass or strength in cohorts of healthy or diabetic older adults who received 2.5 g leucine/meal for 3 and 6 months, respectively. 42 These data are consistent with suggestions that in healthy adults, there is an upper limit to the quantity of protein necessary to maximally stimulate muscle protein synthesis. 43, 44 In a research cohort of healthy young and older adults, ingestion of 90 g of a high-quality, whole-food protein source (12 oz/340 g lean beef ) provided the same 50% increase muscle protein synthesis as a more moderate 30-g protein meal (4 oz/115 g lean beef). 43 In controlled research environments, the quantity of high-quality protein (whey, beef, dairy, eggs, etc) necessary to maximize protein synthesis ranges from approximately 20-35 g/meal. 43 However, it should be immediately apparent that there is no specific or generalizable "optimal amount." While there is low risk and potentially some net anabolic benefit to be gained by exceeding 35 g of high-quality protein/meal, 37,45 practical factors such as body size, energy requirements, body composition goals, physical activity levels, health status, satiety and dentition issues, cost, delivery route (enteral vs parenteral), and the quality of the protein sources consumed should also be considered. 46 In critically ill populations, it is widely recognized that protein requirements are increased. The quantity of protein recommended in critically ill patients ranges from 1.2-2.5 g/kg/ d 1,17,47 but does not consider intake pattern (ie, bolus vs continuous) or protein quality.
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Protein Digestibility and Biological Value
Proteins can be broadly characterized by their origin (plant or animal based), amino acid composition (essential vs nonessential; complete vs incomplete), and their digestibility. The ability to accurately and objectively define protein quality and assign a numerical rank plays an important role in addressing human nutrition requirements, nutrition policy and regulatory affairs, trade, and product development. In a clinical environment, an understanding of the determinants of the various protein quality score metrics allows a more targeted and nuanced dietary prescription to be developed. Several methods have been developed to assess protein quality. Assessment criteria include the essential amino acid content, digestibility, amino acid bioavailability, and the quantity of the limiting essential amino acid.
Biological Value
The biological value (BV) provides an estimate of protein quality by calculating how efficiently the body incorporates dietary protein into muscle and other tissues. Like most methods to assess protein quality, foods containing an abundant supply of essential amino acids score higher than incomplete protein sources (eg, animal vs plant based). However, BV does not account for variations in food preparation (eg, raw vs cooked), digestion, and interaction with other protein-or nitrogen-containing foods.
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Protein Digestibility Corrected Amino Acid Score
Protein Digestibility Corrected Amino Acid Score (PDCAAS) was introduced as the preferred method to assess dietary protein quality in 1991. 52 PDCAAS is calculated by comparing the quantity/ratio of the first limiting essential amino acid in 1 g of a test protein with the amino acids in a reference protein and then correcting for fecal digestibility. [53] [54] [55] Common, well-documented criticisms of PDCAAS include the failure to account for antinutritive factors (eg, trypsin inhibitors, phytic acid), which may compromise absorption; the validity of the preschool-age child amino acid requirement values; the use of fecal instead of ileal digestibility; truncation of some higher quality protein values; and the validity of scores in a mixedfood model 55 ( Table 1) . 
Digestible Indispensable Amino Acid Score
In 2013, the Food and Agriculture Organization (FAO) released the report, "Dietary Protein Quality Evaluation in Human Nutrition," which recommended the newer Digestible Indispensable Amino Acid Score (DIAAS) method replace PDCAAS. DIAAS also compares the ratio of essential amino acids in a "test protein" with the amino acids in a theoretical "best" reference protein but corrects for ileal digestibility and does not truncate scores. 53 While technical challenges remain (eg, animal vs human model, cost, invasive procedures), DIAAS appears to have been broadly accepted by the proteinnutrition research community.
From a clinical perspective, it is important to consider the context and practical translation of dietary recommendations and protein quality scores. For example, the recommended dietary allowance (RDA) for protein is familiar to many but not always correctly interpreted (Figure 2) . 56 Specifically, the RDA for protein (0.8 g/kg/d) is an estimate of the minimum requirement, not an upper limit; does not apply to clinical "unhealthy" populations; and provides general guidance for 24-hour protein intake but not specific, prescriptive mealbased advice. If we establish the RDA as the minimum amount of protein required to avoid deficiency in healthy populations, the concept of moderate, high, and excessive amounts of protein can be more easily understood but remain necessarily subjective and heavily dependent on individual circumstances. For example, exceeding 2 g protein/kg/d (Figure 2 , "high") may be achievable and beneficial, particularly over the short term, in situations where total macronutrient and daily energy intake can be controlled. 47, 57 Protein quality scores and dietary recommendations play a significant role in public nutrition policy and are particularly valuable in the fight against malnutrition. 49, 58 However, the general rank order of various protein-containing foods does not vary tremendously, regardless of the protein quality metric used. Commonly recognized "high-quality proteins" rank highly on all scales, while some incomplete/plant-based proteins consistently score lower (Table 1) . If a healthy individual is meeting his or her energy requirements and consuming a variety and reasonable quantity (ie, >1.2 g/kg/d) of plant and/or animal proteins each day, there is likely little to be gained by exchanging one similar-quality protein source for another. However, in a number of situations, health outcomes may be directly affected by protein quality and food choices. This is perhaps best represented by occasions where only a single protein source is consumed during a specific meal or eating occasion. Energy and other macronutrient/micronutrient requirements notwithstanding, consumption of >20 g of most animal proteins during a meal will likely provide a sufficient quantity and quality of essential amino acids to effectively stimulate tissue anabolism in healthy populations. Conversely, in a whole-food/meal context, a much greater quantity and combination of incomplete proteins would need to be consumed to provide a similar anabolic stimulus as animalbased protein sources. 48 While consuming an increased quantity of food/protein may be feasible for some groups, it could be challenging or contraindicated for others (eg, cost, satiety, dentition).
57,59,60
Protein Supplements: Clinical Application
While whole foods are the cornerstone of most diets, protein supplementation can offer an efficient, convenient, and practical means of stimulating protein anabolism and wound healing, managing satiety, and improving energy balance. 46, 61 Beyond the research environment, the protein supplementation market is a crowded place. In clinical situations where health may be compromised by ineffective nutrition strategies, the quality of a protein supplement should be a primary consideration. This includes circumstances where an individual is experiencing increased catabolism and/or blunted anabolism (eg, illness, injury, physical inactivity), is limited in the quality or quantity of protein able to be consumed as a part of regular [62] [63] [64] A few other protein supplements also score highly on quality ratings (eg, soy isolate, dairy/soy protein blends) and benefit from being used in multiple published research studies. [65] [66] [67] Given protein's broad health benefits and appeal (eg, muscle gain, weight loss, satiety, recovery), it is not surprising that new supplements from a variety of innovative sources continue to appear (Table 2) .
While some of these nontraditional protein supplements address specific market needs (eg, cost, sustainability, plant based), many face challenges inherent in all incomplete proteins: low protein quality/bioavailability scores, a lack of a clear mechanism of action to stimulate anabolism/improve health, and a lack of positive health/phenotype/functional outcomes from reputable research studies or clinical trials. 68 Supplementation with an incomplete protein source may be beneficial and contribute to positive health outcomes if consumed in combination with regular meals or other protein sources that provide an abundant supply of the limiting amino acids. 69 However, if consumed in isolation (eg, meal replacement) or in combination with low-protein regular meals, it is difficult to envision a means by which an incomplete protein supplement could enhance tissue anabolism, reduce protein breakdown, or improve skeletal muscle mass and function. 68 
Effect of Timing of Delivery on Protein Utilization
Acutely ill patient populations face many metabolic demands. Providing adequate nutrition support is universally recognized as important but often compromised by competing medical priorities and logistical challenges. 70 We have previously noted that establishing a dietary framework that orally boluses a moderate amount of high-quality protein, rich in leucine and essential amino acids at each meal, may promote the success of other treatment modalities (eg, physical/occupational therapy, pharmacology, surgical). 48 If a patient is protein malnourished, all treatment strategies will likely be negatively affected. 71 In a simple, descriptive pilot study, we conducted a food tray analysis/plate waste evaluation of the meals presented to a cohort of older patients (aged >70 years) in a geriatric acute care facility (Figure 3) . The data highlight the practical challenges of providing adequate dietary support, even in a specialized care facility. For example, while each meal type (mechanical soft, low sodium, etc) contained a commendable 40 g of protein, the patients consumed <10 g. There are clearly many potential, personal, and situational reasons for this low intake, including taste, food temperature and texture, satiety, food preferences, and chewing/dentition issues. 72, 73 In a population experiencing the catabolic stressors of inactivity, increased age, or disease, 10 g of protein is unlikely to provide a substantial anabolic stimulus. 74 Furthermore, most of the protein consumed was contained in high-sugar/dessert items. In bedrest studies with healthy volunteers, as little as 3-4 days of inactivity can impair whole-body glucose tolerance. 41, 75 In a patient population who may already be insulin resistant, if not type 2 diabetic, the consequence of ingesting a high proportion of simple carbohydrate, in combination with low protein, is metabolically detrimental and likely compromises the overarching goal of protecting muscle health while addressing the root medical problem. 57 Several recent studies have examined the anabolic dose response to the bolus ingestion of protein. Most of these studies have been conducted in healthy populations (young and older adults) and have primarily used a liquid, protein supplement as the "representative meal" (eg, whey, casein, soy, blended protein), although a number of recent studies have examined wholefood proteins such as beef and milk. 43, 62, 67, [76] [77] [78] In general, these studies broadly agree that, depending on quality, somewhere between 20 and 35 g of protein is required to maximally stimulate skeletal muscle protein synthesis in most populations.
If there is a saturable anabolic dose response to protein ingestion, a potential strategy to maximize muscle protein synthesis would be to provide a moderate amount of high-quality protein at multiple meals (ie, breakfast, lunch, dinner). 44, 78 To test this hypothesis, we conducted a 7-day crossover trial to assess 24-hour skeletal muscle protein synthesis following consumption of isoenergetic and isonitrogenous diets in which protein was evenly distributed (ie, approx. 30 g breakfast, 30 g lunch, 30 g dinner) or skewed (10 g breakfast, 15 g lunch, 65 g dinner). Over 24 hours, muscle protein synthesis was 25% higher when protein consumption was evenly distributed vs the more common skewed consumption pattern. 79 This concept continues to be examined in a number of ongoing and recently completed trials, and while it is unlikely to have a rapid, pronounced effect on body composition and muscle function, it may represent a positive incremental step to protect or improve muscle health and augment the efficacy of concomitant therapies.
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Conclusion
In older adults and clinical populations, there is an increased likelihood of anabolic resistance, in which components of signaling pathways fail to respond in a typical/youthful way to the anabolic stimulus provided by protein ingestion. [25] [26] [27] Basic science studies (T1 translational research) focusing on mechanisms of action are a critical prerequisite for clinical intervention trials (T2-T4 translational research). In the protein nutrition/skeletal muscle field, cell signaling studies and the mechanistic exploration of topics such as protein transport and availability provide a target (eg, muscle/strength preservation) and direction (eg, protein/exercise synergy) to frame clinically relevant trials. They cannot always predict or account for the complexities that characterize critical illness. Successful mechanistic studies suggest potential clinical relevance; they do guarantee an outcome. Any list of confounding influences with the potential to compromise a longer term clinical trial outcomes will inevitably be incomplete but includes factors such as habitual/imposed diet, physical in/ activity, comorbid conditions, sleep quantity and quality, and stress. Future research directed at clinical populations should be well grounded and supported by mechanism-driven preliminary data (cell, animal, and/or healthy human cohorts) but tailored to meet the demands and practicalities of compromised, at-risk populations.
Discussion
Jan Wernerman: This maximal protein synthesis zone of 25 to 35 g, how is that documented? Douglas Paddon-Jones: It is documented quite a few ways. Typically it's observed in healthy adults. That's part of that disconnect between optimal patient care and what we can measure in a controlled setting that will give us reliable results without massive variation. The number doesn't really matter, but it's important to get that concept. Clearly there is a dose or a ceiling effect, and these are clearly lower amounts of protein that are going to be less effective. In a clinical environment, I don't think you can pick a particular number and go for it.
Jan Wernerman: There is a lot of literature in the sick critically ill and surgical patients, that bolus feeding may be a better idea. This has been accompanied by methodological issues, of course. Whenever you measure muscle protein synthesis, you come down to the precursor quarrel. I think that is a precaution. Margaret McNoland made a study showing the importance of the precursor problem when you measure muscle protein synthesis. Particularly in skeletal muscle, it makes a difference. The constant infusion method had a lot of problems. Do you see this precursor problem in muscle, or don't you see that?
Douglas Paddon-Jones: We do. Depending on which model you test, you buy some inherent limitations. I think the key is to move beyond it. Like we're trying to do with the bedrest model. In a fairly short period of time, 1 week, we can tie some of these isotopic measures with a hard outcome, to see if we actually have validity. Are we seeing improvements in protein synthesis that translate to a functional outcome? With the increased popularity of the doubly labeled water technique and a few others, you can hit this issue from a few different directions and perhaps mitigate some of the inherent limitations in a specific test. But really the key is, does it improve something tangible? That's always going to be the limitation of just looking at biopsies and identifying a model that can show you a change in function or phenotype. Then the next challenge is taking that to a clinical population. Stuart M. Phillips: I agree with everything you're saying here. I've heard from other people that leucine was once a big thing, but now it's not a big thing. I wonder whether it's because leucine is a branch chain, and as you well know, it's really difficult to get into solution. It's a problem producing solutions that are high enough in leucine. I don't think there's anything equivocal about the fact that it's the amino acid that turns on muscle protein synthesis. There's lots of data to suggest that that's the case. Or is this a situation where industry has not been adding leucine to enteral feedings if we're talking about the ICU? Or is it simply that for years, we've associated leucine with the other branched-chain amino acids and if the other two come along, it's guilt by association. They all share the same transporter. When you give individual crystalline branch chains, including isoleucine and valine, they compete with leucine for uptake. So it may actually reduce the effectiveness of the formula if you don't focus on just leucine alone. Douglas Paddon-Jones: I think there's truth in that. We're doing a bedrest study now. We're showing good effects with leucine. The logical practical extension would be to use whey protein isolate as the delivery vehicle for leucine and some of the other amino acids and hope to see the same robust protective effect. The food science part of it is really hard. You can't easily dissolve leucine; you've got to hide it in something that's got a strong flavor. Yogurt or orange juice is fine. You almost have to weaponize it for these groups. The saving grace is you could get by with such a small amount of leucine compared to some of our historical evil-tasting options.
Jorge A. Coss-Bu: We know that leucine has been extensively studied in pediatrics. Data on neonatal models with sepsis have documented that leucine is important in signaling pathways for increasing protein synthesis. These models actually show that it is the increase in signaling that promotes protein synthesis. Some of these models have been done under conditions that are not feasible in the usual clinical ICU setting, where you keep fixed levels of insulin or the amino acid and then manipulate levels of one with respect to the other. These data have shown that leucine could actually modulate some of the pathways that have to do with degradation. It seems to be important, at least in the neonate. When you compare neonatal versus older animal models, you see a different response. The neonatal model has increased protein turnover. There are limitations of using the whole-body protein model and whether it translates to the whole protein pool. It also has to do with which amino acids you are using for your indicator. Your bedrest data are interesting, and I was trying to translate this into pediatrics. The average length of stay of a pediatric patient is about 3 days. So it's possible that some of these data could be relevant for pediatric patients, as many of our kids stay in the unit over a week or 2 weeks. Claudia R. Morris: I was interested in your meal distribution data. And it brings to the question, is breakfast really the most important meal of the day? A lot of elderly completely skip breakfast altogether. With this idea of bolus feeds 3 times a day or smaller feeds 5 times a day, what is the best approach? You increased the protein in the morning. Is there something specific about morning and circadian rhythms and the effect on protein metabolism, synthesis, and cortisol secretion? Should we be focusing on trying to feed our patients in the morning more than the afternoon? Douglas Paddon-Jones: That's a complicated question and it moves beyond just protein synthesis. One of the other challenges is glucose regulation. Protein at breakfast may improve glycemic control during the morning and thus have a second meal effect, continuing to exert glycemic control with lunch. From a temporal perspective, you've got such a period of time where you could be beneficially improving anabolic balance in the morning. So I don't see why you wouldn't want to feed them protein at breakfast. The same argument in this population could be made for providing that late-night protein snack. If you've got a window of opportunity, and you're not drastically exceeding energy requirements, why not feed them protein? I can't see too many downsides. One of the areas for future investigation revolves around a required refractory period. We know that if you continue to infuse amino acids, graze constantly, you're not going to get a continued improvement in protein synthesis. You do need that refractory up and down period. But how often can you hit people with an anabolic stimulus, maybe 30 g, and get a robust response? And that response in clinical populations may be compromised by elevated protein breakdown, which artificially puts you in a postprandial state. Do you need more leucine to overcome that inherent large precursor pool? Can you give someone a bolus of 30 g of protein every 3 hours and still get repeated anabolic responses? Or do you need greater downtime? Do you need to drop the plasma precursor pool in order to get that rebound effect? Stuart M. Phillips: Three comments. First, bedrest immobility is immensely important, and I think that work needs to be expanded upon, and awareness needs to increase. With the interaction between bedrest and catabolic responses, and the details of configuration, the field needs to be able to design the right kind of interventions. That's just 100% important, even in normal people. We now have data that just sitting recumbent like we do is bad for us. Second, single-dose experiments are biologically important, provide biological insight, and generate hypotheses, but they're single doses. If you had a new blood pressure drug that you wanted to market and you had a single-dose experiment showing it lowered blood pressure, would you get that approved? Of course not. You can use that as the beginning point for doing something that can be translated into clinical practice. But I caution against taking experiments of this kind of metabolic nature, sprung onto people under abnormal and artificial conditions, and then applying this to our patients. And third, I want to comment on the metabolic state of the individual and protein synthesis. If you do something that increases protein synthesis in a person who's in metabolic homeostasis, they will respond by increasing protein breakdown, because they want to stay just the way they are. If I see a study where they augmented protein synthesis in a particular situation, in a single-dose experiment (not allowing for the usual several days of adaptation to a particular diet), then I say show me the protein breakdown. Those subjects will have broken down that protein either concurrently or shortly afterward. What have you benefited? How have you gained? I'm not denying the biological insight, but the practical implication
